James C Root1,2, Charissa Andreotti3, Loretta Tsu4, Timothy M Ellmore4, Tim A Ahles3,5. 1. Neurocognitive Research Laboratory, Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, 641 Lexington Avenue, 7th Floor, New York, NY, 10022, USA. rootj@mskcc.org. 2. Weill Cornell Medical College, New York, NY, USA. rootj@mskcc.org. 3. Neurocognitive Research Laboratory, Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, 641 Lexington Avenue, 7th Floor, New York, NY, 10022, USA. 4. Department of Psychology, Program in Behavioral and Cognitive Neuroscience, The Graduate Center, City University of New York, The City College of the City University of New York, New York, NY, USA. 5. Weill Cornell Medical College, New York, NY, USA.
Abstract
PURPOSE: Our previous retrospective analysis of clinically referred breast cancer survivors' performance on learning and memory measures found a primary weakness in initial encoding of information into working memory with intact retention and recall of this same information at a delay. This suggests that survivors may misinterpret cognitive lapses as being due to forgetting when, in actuality, they were not able to properly encode this information at the time of initial exposure. Our objective in this study was to replicate and extend this pattern of performance to a research sample to increase the generalizability of this finding in a sample in which subjects were not clinically referred for cognitive issues. METHODS: We contrasted learning and memory performance between breast cancer survivors on endocrine therapy 2 to 6 years post-treatment with age- and education-matched healthy controls. We then stratified lower- and higher-performing breast cancer survivors to examine specific patterns of learning and memory performance. Contrasts were generated for four aggregate visual and verbal memory variables from the California Verbal Learning Test-2 (CVLT-2) and the Brown Location Test (BLT): Single-trial Learning: Trial 1 performance, Multiple-trial Learning: Trial 5 performance, Delayed Recall: Long-delay Recall performance, and Memory Errors: False-positive errors. RESULTS: As predicted, breast cancer survivors' performance as a whole was significantly lower on Single-trial Learning than the healthy control group but exhibited no significant difference in Delayed Recall. In the secondary analysis contrasting lower- and higher-performing survivors on cognitive measures, the same pattern of lower Single-trial Learning performance was exhibited in both groups, with the additional finding of significantly weaker Multiple-trial Learning performance in the lower-performing breast cancer group and intact Delayed Recall performance in both groups. CONCLUSIONS: As with our earlier finding of weaker initial encoding with intact recall in a cohort of clinically referred breast cancer survivors, our results indicate this same profile in a research sample of breast cancer survivors. Further, when the breast cancer group was stratified by lower and higher performance, both groups exhibited significantly lower performance on initial encoding, with more pronounced encoding weakness in the lower-performing group. As in our previous research, survivors did not lose successfully encoded information over longer delays, either in the lower- or higher-performing group, again arguing against memory decay in survivors. The finding of weaker initial encoding of information together with intact delayed recall in survivors points to specific treatment interventions in rehabilitation of cognitive dysfunction. IMPLICATIONS FOR CANCER SURVIVORS: The finding of weaker initial encoding of information together with intact delayed recall in survivors points to specific treatment interventions in rehabilitation of cognitive dysfunction and is discussed.
PURPOSE: Our previous retrospective analysis of clinically referred breast cancer survivors' performance on learning and memory measures found a primary weakness in initial encoding of information into working memory with intact retention and recall of this same information at a delay. This suggests that survivors may misinterpret cognitive lapses as being due to forgetting when, in actuality, they were not able to properly encode this information at the time of initial exposure. Our objective in this study was to replicate and extend this pattern of performance to a research sample to increase the generalizability of this finding in a sample in which subjects were not clinically referred for cognitive issues. METHODS: We contrasted learning and memory performance between breast cancer survivors on endocrine therapy 2 to 6 years post-treatment with age- and education-matched healthy controls. We then stratified lower- and higher-performing breast cancer survivors to examine specific patterns of learning and memory performance. Contrasts were generated for four aggregate visual and verbal memory variables from the California Verbal Learning Test-2 (CVLT-2) and the Brown Location Test (BLT): Single-trial Learning: Trial 1 performance, Multiple-trial Learning: Trial 5 performance, Delayed Recall: Long-delay Recall performance, and Memory Errors: False-positive errors. RESULTS: As predicted, breast cancer survivors' performance as a whole was significantly lower on Single-trial Learning than the healthy control group but exhibited no significant difference in Delayed Recall. In the secondary analysis contrasting lower- and higher-performing survivors on cognitive measures, the same pattern of lower Single-trial Learning performance was exhibited in both groups, with the additional finding of significantly weaker Multiple-trial Learning performance in the lower-performing breast cancer group and intact Delayed Recall performance in both groups. CONCLUSIONS: As with our earlier finding of weaker initial encoding with intact recall in a cohort of clinically referred breast cancer survivors, our results indicate this same profile in a research sample of breast cancer survivors. Further, when the breast cancer group was stratified by lower and higher performance, both groups exhibited significantly lower performance on initial encoding, with more pronounced encoding weakness in the lower-performing group. As in our previous research, survivors did not lose successfully encoded information over longer delays, either in the lower- or higher-performing group, again arguing against memory decay in survivors. The finding of weaker initial encoding of information together with intact delayed recall in survivors points to specific treatment interventions in rehabilitation of cognitive dysfunction. IMPLICATIONS FOR CANCER SURVIVORS: The finding of weaker initial encoding of information together with intact delayed recall in survivors points to specific treatment interventions in rehabilitation of cognitive dysfunction and is discussed.
Authors: Jin Fan; Xiaosi Gu; Kevin G Guise; Xun Liu; John Fossella; Hongbin Wang; Michael I Posner Journal: Brain Cogn Date: 2009-03-06 Impact factor: 2.310
Authors: Heather S L Jim; Kristin M Phillips; Sari Chait; Leigh Anne Faul; Mihaela A Popa; Yun-Hsiang Lee; Mallory G Hussin; Paul B Jacobsen; Brent J Small Journal: J Clin Oncol Date: 2012-08-27 Impact factor: 44.544
Authors: Shelli Kesler; S M Hadi Hosseini; Charles Heckler; Michelle Janelsins; Oxana Palesh; Karen Mustian; Gary Morrow Journal: Clin Breast Cancer Date: 2013-05-04 Impact factor: 3.225
Authors: Alexandra M Gaynor; Denise Pergolizzi; Yesne Alici; Elizabeth Ryan; Katrazyna McNeal; Tim A Ahles; James C Root Journal: Brain Stimul Date: 2020-04-27 Impact factor: 8.955
Authors: Catherine M Bender; John D Merriman; Susan M Sereika; Amanda L Gentry; Frances E Casillo; Theresa A Koleck; Margaret Q Rosenzweig; Adam M Brufsky; Priscilla McAuliffe; Yehui Zhu; Yvette P Conley Journal: Oncol Nurs Forum Date: 2018-05-01 Impact factor: 2.172
Authors: Alexandra M Gaynor; Anam Ahsan; Duane Jung; Elizabeth Schofield; Yuelin Li; Elizabeth Ryan; Tim A Ahles; James C Root Journal: J Cancer Surviv Date: 2022-08-08 Impact factor: 4.062
Authors: Michelle C Janelsins; Charles E Heckler; Luke J Peppone; Tim A Ahles; Supriya G Mohile; Karen M Mustian; Oxana Palesh; Ann M O'Mara; Lori M Minasian; Annalynn M Williams; Allison Magnuson; Jodi Geer; Shaker R Dakhil; Judith O Hopkins; Gary R Morrow Journal: J Clin Oncol Date: 2018-09-21 Impact factor: 44.544
Authors: Alexandra M Gaynor; Tim A Ahles; Elizabeth Ryan; Elizabeth Schofield; Yuelin Li; Sunita K Patel; Katrazyna McNeal; Tiffany Traina; James C Root Journal: J Cancer Surviv Date: 2021-08-06 Impact factor: 4.062